Vertex (VRTX) CMO Carmen Bozic earns 11,333 performance-based shares

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Carmen Bozic reported stock awards tied to prior performance-based grants. On 01/22/2026 she acquired 7,866 shares of common stock at $0, increasing her directly held stake to 40,535 shares. On the same date she acquired an additional 3,467 common shares at $0, bringing her directly held total to 44,002 shares.

The first block of 7,866 shares represents earned performance shares from a performance stock unit award granted on 02/01/2023, with shares scheduled to vest on 02/13/2026. The 3,467 shares represent earned performance shares from a performance stock unit award granted on 02/12/2025, with shares scheduled to vest in installments beginning on 02/24/2026.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Bozic Carmen

Role EVP and CMO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,866	$0.00	--
Grant/Award	Common Stock	3,467	$0.00	--

Holdings After Transaction: Common Stock — 40,535 shares (Direct)

Footnotes (1)

1. Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026. Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bozic Carmen

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and CMO

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		A		7,866(1)	A	$0	40,535	D
Common Stock	01/22/2026		A		3,467(2)	A	$0	44,002	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.

2. Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did VRTX executive Carmen Bozic report on this Form 4?

EVP and CMO Carmen Bozic reported the acquisition of two blocks of Vertex common stock on 01/22/2026, both at a price of $0 per share, reflecting the earning of performance-based stock awards rather than open-market purchases.

How many Vertex (VRTX) shares did Carmen Bozic acquire and what is her new total holding?

On 01/22/2026, Carmen Bozic acquired 7,866 Vertex common shares in one transaction and 3,467 shares in another. Her directly held ownership increased first to 40,535 shares and then to 44,002 shares of common stock.

Were the VRTX shares acquired by Carmen Bozic open-market purchases?

No. Both transactions are coded as A (acquisitions) at a price of $0 per share and are described as earned performance shares from prior performance stock unit awards, rather than open-market buying.

What is the origin of the 7,866 Vertex shares reported by Carmen Bozic?

The 7,866 shares represent earned performance shares from a performance stock unit award granted on 02/01/2023. Vertex’s management development and compensation committee certified the level of performance-goal attainment on 01/22/2026, and these shares are scheduled to vest on 02/13/2026.

What is the origin and vesting schedule of the 3,467 VRTX shares reported?

The 3,467 shares are earned performance shares from a performance stock unit award granted on 02/12/2025. The committee certified performance on 01/22/2026, and these shares will vest in installments beginning on 02/24/2026.

What is Carmen Bozic’s role at Vertex Pharmaceuticals (VRTX) in this filing?

In this filing, Carmen Bozic is identified as an officer of Vertex Pharmaceuticals, serving as EVP and CMO, and she reports direct ownership of the common stock involved in the transactions.